Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
ALS Limited
ALS is a testing and inspection company that checks samples — rocks, soil, water, food, and drugs — for clients around the world, mostly mining companies and environmental regulators.
ALS is a testing company. When a mining company pulls a drill core out of the ground, it has no idea how much gold or copper is inside — so it sends a chunk to ALS, which crushes it, dissolves it, and runs it through machines that measure the metals down to tiny concentrations. Same idea for water, soil, food, and pharmaceutical samples: someone needs an independent lab to say what is actually in there, and ALS runs many of the world's biggest networks of those labs.
The business splits into two big pieces. The core is commodities testing for mining companies — geochemistry, metallurgy, and inspection — which rises and falls with exploration budgets, so it booms when miners are spending and slumps when they aren't. The other piece is "life sciences": testing food for contamination, checking water and soil for environmental compliance, and supporting pharmaceutical development. That side is steadier and less cyclical. Together they mean ALS gets paid per sample, per project, and per long-term contract — fees for being the trusted referee with the equipment and accreditations that clients can't easily replicate themselves. The company is headquartered in Brisbane, Australia, and grew over decades through a long string of acquisitions rather than one big bet — it now runs labs across dozens of countries, giving it scale, geographic reach, and the kind of regulatory certifications that take years to earn. It also collects steady cash, which funds dividends, buybacks, and more bolt-on deals. In the twelve months to March 2025, ALS reported revenue of roughly A$2.8 billion, up about 10% on the prior year. The catch is that a chunk of the business is tied to the mining cycle. When commodity prices fall and explorers cut budgets, sample volumes dry up, and ALS feels it. The other vulnerability is plain operational risk: a testing lab lives on its reputation, so a bad result, a safety incident, or lost accreditation can hurt trust. ALS spends heavily on automation to lower its cost per sample, which helps it win volume and defend margins against other big testing networks.
Today ALS is betting on the energy transition — lithium, copper, rare earths — while leaning on the steadier life-sciences and environmental work to smooth out the swings. It is not a glamorous business: it is the unglamorous, necessary step between "we think there's something in the ground" and "we know."
Saved answer · last researched 12 Nov 2026